BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
PDX1
,
Metabolism of xenobiotics
,
Allergy to pollen
,
Hippocampus
,
Biofuel
,
Lovastatin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
response to interleukin-2
(biogroup)
Summary
General Info
Body Atlas
Most Correlated Tissues
Medulla
Midbrain
Vestibular nuclei superior
Cerebral cortex
Substantia nigra pars compacta
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Chlamydial infection
Chronic interstitial cystitis
Contact dermatitis
Protozoan infection
Ebola virus disease
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
GSK-1059615
A 443654
CGP 60474
aldesleukin
BMS 387032
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
FGFR1
MIR125B2
TLK2
UBE4A
CRKL
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
L1000 CMAP - Colorectal cancer HT29.311 cells with CRISPR-targeted gene knockouts
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Bone marrow CD34 cells treated with small molecule perturbagens
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Neural progenitor NPC.CAS9 cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Antigenic and immunogenic properties of recombinant proteins consisting of two immunodominant Africa…
A Protease Activatable Interleukin-2 Fusion Protein Engenders Antitumor Immune Responses by Interfer…
The Role of High Dose Interleukin-2 in the Era of Targeted Therapy.
Rare Genetic Variants of Large Effect Influence Risk of Type 1 Diabetes.
When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-…
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Le…
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ